New enteric-coated high-lipase pancreatic extract in the treatment of pancreatic steatorrhea.
We studied a new enteric-coated pancreatic extract with very high lipase content in 12 patients with steatorrhea due to chronic pancreatitis. Fecal fat was measured under standard dietary conditions (100 g lipid/day) with no enzyme supplementation and during treatment with 75,000, 150,000, or 225,000 IU of lipase per day. The median fecal fat output (g/day) was significantly (p < 0.005) lower after each increase in dosage: basal, 20.5 (range, 10.3-92.2); 3 cps/day at meals, 13.3 (6.4-38.2); 6 cps/day, 9.9 (4.8-31.4); 9 cps/day, 7.3 (2.6-17.3). For the five patients with a basal fecal fat output of < 15 g/day, steatorrhea was totally corrected by 3 cps a day. Of the seven patients with more severe steatorrhea, the fecal fat output of only two was not normalized with the highest dose of 9 cps/day: for one it was reduced to 13.3 g/day from a basal of 92.2 g/day and for the other to 17.3 g/day from 25.4 g/day. This pilot study demonstrates that the tested pancreatic extract very effectively corrects pancreatic steatorrhea in a simple low-dose regimen. Good compliance can be expected.
Malesci
A
A
Istituto di Scienze Biomediche S. Paolo, II Scuola di Specializzazione in Gastroenterologia, University of Milan, Italy.
Mariani
A
A
Mezzi
G
G
Bocchia
P
P
Basilico
M
M
D000328:Adult; D000368:Aged; D002214:Capsules; D002446:Celiac Disease / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D008055:Lipids / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010194:Pancreatin / Q000008:administration & dosage* / Q000627:therapeutic use; D010195:Pancreatitis / Q000150:complications / Q000378:metabolism; D010865:Pilot Projects; D013608:Tablets, Enteric-Coated
D002214:Capsules; D008055:Lipids; D013608:Tablets, Enteric-Coated; D010194:Pancreatin